Our results demonstrate that the CD4/CD8 ratio and CD19+ cell counts were higher in the PR+CR group than in the SD group, suggesting that stronger immune status predicts the short-term efficacy of prostate cancer patients treated with carbon ions. This evidence concerns the gene CD4 and Familial prostate cancer.